Sofiva Genomics Co.,Ltd.
Research Sofiva Genomics Co.,Ltd. (6615.TWO) on Bullrun: market cap TWD 717.98M, P/E 50.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6615.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyTWD
- Market capTWD 717.98M
- P/E50.4
- Financial periodQ2 2026
- RevenueTWD 97.07M
- Net incomeTWD 5.43M
- Free cash flowTWD 3.62M
- Gross margin27.2%
Valuation Snapshot
latest market cap is TWD 717.98M; P/E is 50.4.
Peer valuation comparison
Latest P/E is 50.38x versus a Healthcare sector median of 21.8x (131.1% above).
Latest P/E is 50.38x versus a Taiwan median of 18.67x (169.9% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 717.98M | 50.4 | n/a | 0.3 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.3 TWD.
About Sofiva Genomics Co.,Ltd.
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sofiva Genomics Co.,Ltd.'s market cap?
Sofiva Genomics Co.,Ltd.'s market capitalization is TWD 717.98M.
What is Sofiva Genomics Co.,Ltd.'s P/E ratio?
Sofiva Genomics Co.,Ltd.'s price-to-earnings (P/E) ratio is 50.4.
What does Sofiva Genomics Co.,Ltd. do?
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally.